spacer
home > ebr > summer 2007 > hiv: drug market dynamics
PUBLICATIONS
European Biopharmaceutical Review

HIV: Drug Market Dynamics

Mansi Shah and Lisette Oversteegen at DataMonitor investigate the market potential of HIV retrovirals and predict the impact of patent expiry

Ever since the discovery of the human immunodeficiency virus (HIV) in 1984, the prevalence of HIV patients has been increasing worldwide, and by 2006 there were 39.5 million with the disease (1). The six major Western markets (6MM) (2) represent the largest HIV drug market, generating approximately $8.2 billion of sales in 2006, following a strong compound annual growth rate (CAGR) of 13.1 per cent between 2003 and 2006 (3).

Although small compared to sectors such as the antibacterial market, the HIV market is one of the fastestgrowing within the infectious diseases sector. Factors driving this growth include the growing number of heterosexual transmissions, immigration from countries with a high HIV prevalence, and a suggested increase in high-risk sexual behaviour among homosexual men. At the same time, the lifeprolonging effects of antiretroviral therapies have turned HIV into a chronic disease.

Although the 6MM represent the most commercially significant HIV markets, they account for only three to six per cent of the globally infected population – over 95 per cent of HIV patients live in the developing world, with sub-Saharan Africa accounting for the vast majority (4). The growth in patient numbers in the Western markets is lower than the six per cent global growth in patient population from 2004 to 2006 as a result of greater disease awareness (1). Meanwhile, growth in emerging markets is driven by the fact that there are fewer and less well-funded HIV/AIDS educational programmes, the drug distribution infrastructure is less effective and drugs are unaffordable for patients.

COMBINATION DRUGS

The HIV market has witnessed a rapid development since the introduction of the first antiretroviral in 1987 (GlaxoSmithKline’s Retrovir, zidovudine). This drug belongs to the nucleoside reverse transcriptase inhibitor class (NRTIs). Since this was the first class of antiretrovirals to become available, the majority of patients were placed on high doses of monotherapy, which eventually led to toxicity and resistance. The introduction of protease inhibitors (PIs) in 1995 provided physicians with extra options to treat patients and initiated the use of a combination of drugs from different classes, more commonly known as highly active antiretroviral therapy (HAART).

This class’s novel mechanism of action enabled synergistic action with NRTIs in combination therapy, which partly addressed the problem of resistance. However, there were a number of issues when the first PIs launched, including patient compliance due to high pill burden, pharmacokinetic problems and side effects – such as lipodystrophy, liver toxicity and diabetes. Recently launched PIs have been designed to address these issues: drugs such as Kaletra, Reyataz and Prezista (developed by Abbott Laboratories, Bristol Meyers-Squibb (BMS) and Tibotec respectively) have more favourable side-effect profiles and have a significantly lower pill burden compared to the older PIs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mansi Shah joined Datamonitor in 2006 as an Associate Analyst and has since authored a number of market analysis reports for the company in the field of infectious diseases, focusing in particular on HIV, respiratory tract infections and nosocomial infections. She is now an HIV/Infectious Diseases Analyst. Prior to Datamonitor, Mansi completed a BSc (Hons) degree in Natural Sciences at Birmingham University, majoring in Biochemistry and Maths.

Lisette Oversteegen joined Datamonitor in October 2005 and has since focused on market analysis in the field of infectious and respiratory diseases, including HIV, respiratory syncytial virus, asthma, COPD, cystic fibrosis and allergic rhinitis. She is now an HIV/Infectious Diseases Analyst. Prior to Datamonitor, Lisette completed a Master’s in Public Health at Maastricht University, the Netherlands, specialising in work and health, and a Bachelor’s in Occupational Therapy, at Amsterdam University.

spacer
Mansi Shah
spacer
spacer
spacer
Lisette Oversteegen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

‘FDA should withdraw ANDAs’, and ‘new technologies could bring massive improvements in efficiency’ if implemented correctly

Amsterdam, 21st October 2019: CPhI Worldwide – the world’s largest pharma event taking place in Frankfurt (5th-7th November 2019) – has released the first part of its eponymous 2019 Annual Report. Experts Bikash Chatterjee, President and Chief Science Officer at Pharmtech Associates and Girish Malhotra, President of EPCOT International discuss how manufacturing could be revolutionised by new technologies, but warn, that regulators must change to prevent hindering future innovation.
More info >>

White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement